147 related articles for article (PubMed ID: 19034336)
1. Renal transplantation in the modern immunosuppressive era in Spain: four-year results from a multicenter database focus on post-transplant cardiovascular disease.
Morales JM; Marcén R; Andrés A; Molina MG; Castillo DD; Cabello M; Capdevila L; Campistol JM; Oppenheimer F; Serón D; Vernet SG; Lampreave I; Valdés F; Anaya F; Escuín F; Arias M; Pallardó L; Bustamante J
Kidney Int Suppl; 2008 Dec; (111):S94-9. PubMed ID: 19034336
[TBL] [Abstract][Full Text] [Related]
2. Tacrolimus-based, steroid-free regimens in renal transplantation: 3-year follow-up of the ATLAS trial.
Krämer BK; Klinger M; Vítko Š; Glyda M; Midtvedt K; Stefoni S; Citterio F; Pietruck F; Squifflet JP; Segoloni G; Krüger B; Sperschneider H; Banas B; Bäckman L; Weber M; Carmellini M; Perner F; Claesson K; Marcinkowski W; Ostrowski M; Senatorski G; Nordström J; Salmela K
Transplantation; 2012 Sep; 94(5):492-8. PubMed ID: 22858806
[TBL] [Abstract][Full Text] [Related]
3. Open prospective study to evaluate cardiovascular risk factors and renal function in 2 dosage regimens of tacrolimus combined with mycophenolate mofetil and steroids in renal transplant patients: 5-year results.
Chamienia A; Dębska-Ślizień A; Król E; Biedunkiewicz B; Rutkowski B
Transplant Proc; 2014 Oct; 46(8):2714-8. PubMed ID: 25380901
[TBL] [Abstract][Full Text] [Related]
4. A randomized trial with steroids and antithymocyte globulins comparing cyclosporine/azathioprine versus tacrolimus/mycophenolate mofetil (CATM2) in renal transplantation.
Vacher-Coponat H; Moal V; Indreies M; Purgus R; Loundou A; Burtey S; Brunet P; Moussi-Frances J; Daniel L; Dussol B; Berland Y
Transplantation; 2012 Feb; 93(4):437-43. PubMed ID: 22228415
[TBL] [Abstract][Full Text] [Related]
5. Tacrolimus in pancreas transplantation: a multicenter analysis. Tacrolimus Pancreas Transplant Study Group.
Gruessner RW
Clin Transplant; 1997 Aug; 11(4):299-312. PubMed ID: 9267719
[TBL] [Abstract][Full Text] [Related]
6. Late evolution of kidney transplants in elderly donors and recipients receiving initial immunosuppressant treatment with daclizumab, mycophenolate mofetil, and delayed introduction of tacrolimus.
González-Roncero FM; Gentil-Govantes MÁ; González-Molina M; Rivero M; Cantarell C; Alarcón A; Franco A; Sánchez-Plumed J; Lampreabe I; Lauzurica R; González E; Romero R; Ruiz-San Millán JC; Osuna A
Nefrologia; 2012 Jul; 32(4):446-54. PubMed ID: 22806279
[TBL] [Abstract][Full Text] [Related]
7. Rescue therapy with tacrolimus and mycophenolate mofetil does not prevent deterioration of graft function in C4d-positive chronic allograft nephropathy.
Schwarz C; Regele H; Huttary N; Wahrmann M; Exner M; Nagy-Bojarsky K; Kletzmayr J; Hörl WH; Böhmig GA
Wien Klin Wochenschr; 2006 Jul; 118(13-14):397-404. PubMed ID: 16865644
[TBL] [Abstract][Full Text] [Related]
8. Long-term renal transplant function in recipient of simultaneous kidney and pancreas transplant maintained with two prednisone-free maintenance immunosuppressive combinations: tacrolimus/mycophenolate mofetil versus tacrolimus/sirolimus.
Gallon LG; Winoto J; Chhabra D; Parker MA; Leventhal JR; Kaufman DB
Transplantation; 2007 May; 83(10):1324-9. PubMed ID: 17519781
[TBL] [Abstract][Full Text] [Related]
9. A Prospective Randomized, Comparative Trial of High-Dose Mizoribine Versus Mycophenolate Mofetil in Combination With Tacrolimus and Basiliximab for Living Donor Renal Transplant: A Multicenter Trial.
Ishida H; Takahara S; Amada N; Tomikawa S; Chikaraishi T; Takahashi K; Uchida K; Akiyama T; Tanabe K; Toma H;
Exp Clin Transplant; 2016 Oct; 14(5):518-525. PubMed ID: 27733107
[TBL] [Abstract][Full Text] [Related]
10. Graft survival following living-donor renal transplantation: a comparison of tacrolimus and cyclosporine microemulsion with mycophenolate mofetil and steroids.
Bunnapradist S; Daswani A; Takemoto SK
Transplantation; 2003 Jul; 76(1):10-5. PubMed ID: 12865780
[TBL] [Abstract][Full Text] [Related]
11. Early steroid withdrawal therapy in renal transplant recipients: a steroid-free sirolimus and CellCept-based calcineurin inhibitor-minimization protocol.
Jaber JJ; Feustel PJ; Elbahloul O; Conti AD; Gallichio MH; Conti DJ
Clin Transplant; 2007; 21(1):101-9. PubMed ID: 17302598
[TBL] [Abstract][Full Text] [Related]
12. Tacrolimus plus low-dose mycophenolate mofetil in renal transplant recipients: better 2-year graft and patient survival than with a higher mycophenolate mofetil dose.
Kocak H; Yakupoglu U; Karatas GU; Yavuz A; Gurkan A; Erdogan O; Ersoy FF; Yakupoglu G; Demirbas A; Tuncer M
Transplant Proc; 2005 Sep; 37(7):3009-11. PubMed ID: 16213288
[TBL] [Abstract][Full Text] [Related]
13. 15-year follow-up of a multicenter, randomized, calcineurin inhibitor withdrawal study in kidney transplantation.
Roodnat JI; Hilbrands LB; Hené RJ; de Sévaux RG; Smak Gregoor PJ; Kal-van Gestel JA; Konijn C; van Zuilen A; van Gelder T; Hoitsma AJ; Weimar W
Transplantation; 2014 Jul; 98(1):47-53. PubMed ID: 24521775
[TBL] [Abstract][Full Text] [Related]
14. Three-year observational follow-up of a multicenter, randomized trial on tacrolimus-based therapy with withdrawal of steroids or mycophenolate mofetil after renal transplant.
Pascual J; van Hooff JP; Salmela K; Lang P; Rigotti P; Budde K
Transplantation; 2006 Jul; 82(1):55-61. PubMed ID: 16861942
[TBL] [Abstract][Full Text] [Related]
15. Risk factors of long-term graft loss in renal transplant recipients with chronic allograft dysfunction.
Khalkhali HR; Ghafari A; Hajizadeh E; Kazemnejad A
Exp Clin Transplant; 2010 Dec; 8(4):277-82. PubMed ID: 21143092
[TBL] [Abstract][Full Text] [Related]
16. Impact of tacrolimus and mycophenolate mofetil regimen vs. a conventional therapy with steroids on cardiovascular risk in liver transplant patients.
Cuervas-Mons V; Herrero JI; Gomez MA; González-Pinto I; Serrano T; de la Mata M; Fabregat J; Gastaca M; Bilbao I; Varo E; Sánchez-Antolín G; Rodrigo J; Espinosa MD
Clin Transplant; 2015 Aug; 29(8):667-77. PubMed ID: 25924549
[TBL] [Abstract][Full Text] [Related]
17. Comparison of four different immunosuppression protocols without long-term steroid therapy in kidney recipients monitored by surveillance biopsy: five-year outcomes.
Anil Kumar MS; Irfan Saeed M; Ranganna K; Malat G; Sustento-Reodica N; Kumar AM; Meyers WC
Transpl Immunol; 2008 Nov; 20(1-2):32-42. PubMed ID: 18773960
[TBL] [Abstract][Full Text] [Related]
18. Induction Therapies in Live Donor Kidney Transplantation on Tacrolimus and Mycophenolate With or Without Steroid Maintenance.
Tanriover B; Zhang S; MacConmara M; Gao A; Sandikci B; Ayvaci MU; Mete M; Tsapepas D; Rajora N; Mohan P; Lakhia R; Lu CY; Vazquez M
Clin J Am Soc Nephrol; 2015 Jun; 10(6):1041-9. PubMed ID: 25979971
[TBL] [Abstract][Full Text] [Related]
19. Risk Factors Affecting Graft and Patient Survivals After Transplantation From Deceased Donors in a Developing Country: A Single-Center Experience.
Ayar Y; Ersoy A; Ocakoglu G; Yildiz A; Oruc A; Soyak H; Calapkulu M; Sahin AB; Topal NB; Okeer E; Coskun B; Kaygisiz O; Kordan Y; Vuruskan H
Transplant Proc; 2017 Mar; 49(2):270-277. PubMed ID: 28219583
[TBL] [Abstract][Full Text] [Related]
20. Mycophenolate mofetil in renal transplantation: 3-year results from the placebo-controlled trial. European Mycophenolate Mofetil Cooperative Study Group.
Transplantation; 1999 Aug; 68(3):391-6. PubMed ID: 10459543
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
